The FDA approved Intellia Therapeutics’ one-time in vivo CRISPR medicine lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, clearing a key regulatory step after successful Phase 3 results. Lonvo-z uses an mRNA-lipid nanoparticle delivery system designed to treat the unpredictable, potentially life-threatening swelling attacks of HAE. The BLA approval follows reported Phase 3 HAELO trial outcomes published in the New England Journal of Medicine. In interviews cited with the approval coverage, investigators emphasized that while existing therapies can prevent attacks, unpredictability and quality-of-life burdens remain major unmet needs. This approval strengthens the case for mRNA-LNP delivered genome editing as a practical therapeutic option beyond the exploratory stage, and it adds momentum for wider adoption of gene-editing modalities in rare diseases.